Skip to main content
Erschienen in: International Journal of Hematology 4/2017

09.11.2016 | Case Report

Primary autoimmune myelofibrosis: a case report and review of the literature

verfasst von: Yasmin Abaza, C. Cameron Yin, Carlos E. Bueso-Ramos, Sa A. Wang, Srdan Verstovsek

Erschienen in: International Journal of Hematology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune myelofibrosis is a rare, distinct clinicopathological entity that can occur in isolation (primary) or in association with systemic autoimmune disorders (secondary), such as systemic lupus erythematosus and Sjogren’s syndrome. This disease is characterized by isolated or combined chronic cytopenias associated with autoimmune phenomena and bone-marrow fibrosis. Due to the rarity of this disease, patients are frequently misdiagnosed as having primary myelofibrosis, the most common form of bone-marrow fibrosis. Distinguishing between both disease entities is essential given the drastic therapeutic and prognostic differences between both disorders. We report a case of primary autoimmune myelofibrosis presenting with severe isolated anemia refractory to multiple lines of therapy. This patient was initially misdiagnosed as primary myelofibrosis. The absence of the characteristic features of primary myelofibrosis and the lack of a clonal abnormality on cytogenetic and molecular studies, particularly JAK2, CALR, and MPL mutation analyses, confirmed the absence of an aberrant neoplastic process. Furthermore, the presence of monoclonal T-cell receptor gamma gene rearrangements delineated the presence of an autoimmune disorder supporting our diagnosis of primary autoimmune myelofibrosis.
Literatur
1.
Zurück zum Zitat Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954–70.CrossRefPubMed Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954–70.CrossRefPubMed
2.
Zurück zum Zitat McCarthy DM. Annotation. Fibrosis of the bone marrow: content and causes. Br J Haematol. 1985;59:1–7.CrossRefPubMed McCarthy DM. Annotation. Fibrosis of the bone marrow: content and causes. Br J Haematol. 1985;59:1–7.CrossRefPubMed
3.
Zurück zum Zitat Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351–62.CrossRefPubMed Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351–62.CrossRefPubMed
5.
Zurück zum Zitat Harrison JS, Corcoran KE, Joshi D, Sophacleus C, Rameshwar P. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol. 2006;81:51–8.CrossRefPubMed Harrison JS, Corcoran KE, Joshi D, Sophacleus C, Rameshwar P. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol. 2006;81:51–8.CrossRefPubMed
6.
Zurück zum Zitat Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.CrossRefPubMed Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.CrossRefPubMed
7.
Zurück zum Zitat Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128–38.CrossRefPubMedPubMedCentral Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128–38.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Rizzi R, Pastore D, Liso A, et al. Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma. 2004;45:561–6.CrossRefPubMed Rizzi R, Pastore D, Liso A, et al. Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma. 2004;45:561–6.CrossRefPubMed
9.
Zurück zum Zitat Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore). 1994;73:145–52.CrossRef Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore). 1994;73:145–52.CrossRef
10.
Zurück zum Zitat Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72:8–12.CrossRefPubMed Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol. 2003;72:8–12.CrossRefPubMed
11.
Zurück zum Zitat Vergara-Lluri ME, Piatek CI, Pullarkat V, et al. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014;45:2183–91.CrossRefPubMed Vergara-Lluri ME, Piatek CI, Pullarkat V, et al. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol. 2014;45:2183–91.CrossRefPubMed
12.
Zurück zum Zitat Chalayer E, Ffrench M, Cathebras P. Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. Springerplus. 2014;3:349.CrossRefPubMedPubMedCentral Chalayer E, Ffrench M, Cathebras P. Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. Springerplus. 2014;3:349.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.PubMed Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.PubMed
14.
Zurück zum Zitat Jaffe ES, Krenacs L, Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol. 1997;8(Suppl 2):17–24.CrossRefPubMed Jaffe ES, Krenacs L, Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol. 1997;8(Suppl 2):17–24.CrossRefPubMed
15.
Zurück zum Zitat Wlodarski MW, Nearman Z, Jankowska A, et al. Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol. 2008;83:589–601.CrossRefPubMed Wlodarski MW, Nearman Z, Jankowska A, et al. Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol. 2008;83:589–601.CrossRefPubMed
16.
Zurück zum Zitat Barcellini W, Revelli N, Imperiali FG, et al. Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity. Int J Hematol. 2010;91:762–9.CrossRefPubMed Barcellini W, Revelli N, Imperiali FG, et al. Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity. Int J Hematol. 2010;91:762–9.CrossRefPubMed
17.
Zurück zum Zitat Barcellini W, Iurlo A, Radice T, et al. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013;37:1509–15.CrossRefPubMed Barcellini W, Iurlo A, Radice T, et al. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013;37:1509–15.CrossRefPubMed
Metadaten
Titel
Primary autoimmune myelofibrosis: a case report and review of the literature
verfasst von
Yasmin Abaza
C. Cameron Yin
Carlos E. Bueso-Ramos
Sa A. Wang
Srdan Verstovsek
Publikationsdatum
09.11.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2129-5

Weitere Artikel der Ausgabe 4/2017

International Journal of Hematology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.